Welcome to our dedicated page for Novo-Nordisk A S SEC filings (Ticker: NONOF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for NOVO NORDISK A/S B NEW (NONOF) provides access to disclosures filed by Novo Nordisk A/S as a foreign issuer. These filings give detailed insight into the company that underlies NONOF, including its therapeutic focus, clinical programmes, governance decisions and insider transactions.
Through Form 6-K and other submissions, Novo Nordisk reports material developments such as FDA approval of the Wegovy pill, a once-daily oral semaglutide 25 mg tablet for weight management and reduction of major adverse cardiovascular events in adults with obesity or overweight and specific cardiovascular conditions. Filings also describe the OASIS phase 3 programme in obesity, phase 2 results for amycretin in type 2 diabetes, and outcomes of the evoke and evoke+ phase 3 trials in Alzheimer’s disease.
Regulatory documents further cover corporate matters. Extraordinary general meeting resolutions detail changes in the Board of Directors and the composition of committees like the Audit, Remuneration, People and Governance, and Research & Development Committees. Separate filings disclose trading in Novo Nordisk shares by board members, executives and associated persons, in line with market abuse rules, providing transparency around insider activity in Novo Nordisk B shares listed on Nasdaq Copenhagen and ADRs listed on the New York Stock Exchange.
On Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that explain the key points in plain language. Users researching NONOF can use this page to quickly understand what Novo Nordisk reports in its official documents, from clinical data and product approvals to governance changes and insider transactions, without reading every page of each filing.
Novo Nordisk A/S is executing a share repurchase programme as part of an overall plan to buy back up to DKK 15 billion of B shares over a 12‑month period starting 4 February 2026. A specific tranche targets up to DKK 3.8 billion of B shares from 4 February to 4 May 2026.
From 4 February to 20 February 2026, the company repurchased 2,750,000 B shares at an average price of DKK 306.18, for a total of DKK 841,997,435. After these transactions, Novo Nordisk holds 20,139,799 B shares of DKK 0.10 as treasury shares, equal to 0.5% of its 4,465,000,000 total A and B shares.
Novo Nordisk reported headline phase 3 results from the REDEFINE 4 obesity trial comparing once-weekly CagriSema 2.4 mg/2.4 mg with tirzepatide 15 mg over 84 weeks in 809 people with obesity and comorbidities.
Using the efficacy estimand assuming full adherence, CagriSema led to 23.0% weight loss at 84 weeks versus 25.5% with tirzepatide. Under the treatment-regimen estimand, weight loss was 20.2% with CagriSema and 23.6% with tirzepatide. The primary endpoint of demonstrating non-inferiority of CagriSema to tirzepatide on weight loss was not achieved.
CagriSema showed a generally safe, well-tolerated profile with mostly mild to moderate gastrointestinal side effects that lessened over time. Novo Nordisk has submitted CagriSema for U.S. approval for weight management based on other pivotal trials, with an FDA decision anticipated by late 2026 and additional REDEFINE 11 and higher-dose CagriSema phase 3 readouts planned through 2027.
Novo Nordisk A/S has called its Annual General Meeting for 26 March 2026 at 14:00 (CET). The meeting will be held as a combined physical and virtual event, allowing shareholders to attend at Bella Center in Copenhagen or participate online by computer or mobile device.
Shareholders are encouraged to submit proxies or votes by correspondence in advance, with practical details provided in the accompanying meeting notice and via a live webcast. All shareholder-elected Board members are up for election, and the Board proposes re-electing Lars Rebien Sørensen as Chair, Cees de Jong as Vice Chair, and several other members, while nominating Helena Saxon, Jan van de Winkel and Ramona Sequeira as new Board members.
Novo Nordisk is updating investors on its ongoing share repurchase programme. The company plans to buy back B shares for up to DKK 15 billion over a 12‑month period starting 4 February 2026, including up to DKK 3.8 billion between 4 February and 4 May 2026.
As of 13 February 2026, Novo Nordisk has repurchased 1,750,000 B shares at an average price of DKK 305.03, for a total of DKK 533,796,640. The company now holds 19,139,799 B shares as treasury shares, equal to 0.4% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S reports insider transactions by its Chief Financial Officer, Karsten Munk Knudsen, in accordance with market abuse regulation. As Executive Vice President and CFO, he notified two sales of Novo Nordisk B shares.
On 10 February 2026, he sold 26,246 shares at a price of DKK 315.60 per share, for an aggregated amount of DKK 8,283,237.60, executed through JANE STREET NETHERLANDS B.V. He also sold 311 shares at DKK 315.70 per share, for an aggregated amount of DKK 98,182.70, on CBOE EUROPE - DXE PERIODIC (NL). These trades were reported as initial notifications under the rules for persons discharging managerial responsibilities and their closely associated persons.
Novo Nordisk A/S reports an insider share transaction by Executive Vice President for R&D and Chief Scientific Officer Martin Holst Lange. He sold 22,000 Novo Nordisk B shares at DKK 319.80 per share, for a total of DKK 7,035,600.
The transaction, carried out on 9 February 2026 on Nasdaq Copenhagen, was described as a sale of shares to cover tax on shares transferred under the company’s Long Term Incentive programme.
Novo Nordisk A/S is executing a large share repurchase programme of up to DKK 15 billion over 12 months beginning 4 February 2026. Within this, it plans to buy back B shares for up to DKK 3.8 billion from 4 February to 4 May 2026.
As of 6 February 2026, Novo Nordisk has repurchased 750,000 B shares at an average price of DKK 296.40, with a total value of DKK 222,297,903. Incentive plan activity led to a net transfer out of 3,841,954 B shares. The company now holds 18,283,326 B shares as treasury shares, equal to 0.4% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S has reported several insider transactions by board and executive members under its Long Term Incentive programme, as required by market abuse regulations. Shares of Novo Nordisk B (ISIN DK0062498333) were transferred at a price of DKK 0.00 to multiple senior leaders, including Board member Liselotte Sofie Hyveled (1,085 shares) and President and CEO Maziar Mike Doustdar (28,049 shares).
Executives such as David Moore, Emil Kongshøj Larsen, Tania Sabroe, Martin Holst Lange, Thilde Hummel Bøgebjerg, Karsten Munk Knudsen, Kasper Bødker Mejlvang and Ludovic Helfgott also received share transfers ranging from 5,009 to 26,557 shares. In addition, David Moore sold 6,845 shares and Emil Kongshøj Larsen sold 3,645 shares on Nasdaq Copenhagen at DKK 304.72 per share to cover taxes related to these incentive share transfers.
Novo Nordisk A/S is launching its 2026 share repurchase programme of up to DKK 15 billion. As part of this, it has started a new buyback of up to DKK 3.8 billion to run from 4 February 2026 through 4 May 2026.
The company states the purpose is to reduce its share capital and meet obligations from share-based incentive programmes, with a maximum of 400,000,000 B shares of DKK 0.10 in total that can be purchased during the trading period. The programme relies on an existing repurchase authorisation granted at the 27 March 2025 Annual General Meeting and its continuation beyond 26 March 2026 will depend on renewed approval at the 2026 meeting.
The buyback will follow EU Market Abuse Regulation Article 5 and related Safe Harbour Rules, with Nordea Danmark acting as lead manager.
Novo Nordisk A/S has issued its annual report for 2025. The report is available on the company’s investor website and is also attached in iXBRL format for electronic analysis.
Novo Nordisk is a global healthcare company founded in 1923 and headquartered in Denmark. It focuses on defeating serious chronic diseases, with a heritage in diabetes and efforts to pioneer scientific breakthroughs, expand access to medicines, and work toward prevention and cures.
The company employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares trade on Nasdaq Copenhagen, and its American depositary receipts trade on the New York Stock Exchange under the symbol NVO.